COMMUNIQUÉS West-GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
04/08/2025
WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Accumulus Synergy Spins Out Accumulus Technologies to Scale Proven Regulatory Platform and Accelerate Global Access to Therapies
04/08/2025
BURLINGAME, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- In a bold move to accelerate regulatory innovation and meet growing global demand, Accumulus Synergy, a nonprofit industry association, today announced the formation [...]
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
04/08/2025
WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
04/08/2025
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY ® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and [...]
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
04/08/2025
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be [...]
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
04/08/2025
BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have [...]
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
04/08/2025
BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered [...]
Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors
04/08/2025
ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the AKT1 E17K [...]
OraSure Appoints Anne Messing as Chief Commercial Officer
04/08/2025
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing [...]
Kraig Biocraft Laboratories Sets New Production Record and Advances Spider Silk Reeling with Successful Implementation of Automated Reeling Equipment
04/08/2025
Improved processing unlocks greater quality and efficiency for recombinant spider silk fiber ANN ARBOR, Mich., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs [...]
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
04/08/2025
Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo’s digital asset treasury [...]
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
04/08/2025
Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activity Study conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout model First clinical study for simufilam in TSC- [...]
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
04/08/2025
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage [...]
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
04/08/2025
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE [...]
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
04/08/2025
XOMA Royalty adds milestone and royalty economics associated with two partnered assets EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA [...]
MediWound to Report Second Quarter 2025 Financial Results
04/08/2025
MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Glass House Brands Provides Updates to Recent Events
04/08/2025
LONG BEACH, Calif. and TORONTO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
04/08/2025
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by [...]

Pages